Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 77.56
2
Low Debt Company with Strong Long Term Fundamental Strength
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROE of 11.50%, it has a very attractive valuation with a 0.85 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 288,765 Million (Small Cap)
7.00
NA
0.01%
0.04
9.55%
1.00
Revenue and Profits:
Net Sales:
43,094 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,441 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.16%
0%
0.16%
6 Months
11.07%
0%
11.07%
1 Year
-21.27%
0%
-21.27%
2 Years
41.81%
0%
41.81%
3 Years
27.51%
0%
27.51%
4 Years
13.23%
0%
13.23%
5 Years
15.66%
0%
15.66%
Tsumura & Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.00%
EBIT Growth (5y)
16.28%
EBIT to Interest (avg)
77.56
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.44
Tax Ratio
24.22%
Dividend Payout Ratio
31.84%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
9.80%
ROE (avg)
8.00%
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
0.85
EV to EBIT
6.31
EV to EBITDA
4.94
EV to Capital Employed
0.85
EV to Sales
1.40
PEG Ratio
0.08
Dividend Yield
0.01%
ROCE (Latest)
13.48%
ROE (Latest)
11.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2020
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
43,094.00
43,690.00
-1.36%
Operating Profit (PBDIT) excl Other Income
10,684.00
13,381.00
-20.16%
Interest
147.00
112.00
31.25%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4,441.00
11,396.00
-61.03%
Operating Profit Margin (Excl OI)
179.10%
242.00%
-6.29%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -1.36% vs 17.97% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -61.03% vs 162.40% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
181,093.00
150,845.00
20.05%
Operating Profit (PBDIT) excl Other Income
51,296.00
30,772.00
66.70%
Interest
518.00
330.00
56.97%
Exceptional Items
-32.00
0.00
Consolidate Net Profit
34,523.00
18,046.00
91.31%
Operating Profit Margin (Excl OI)
221.60%
132.70%
8.89%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 20.05% vs 7.71% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 91.31% vs 3.80% in Mar 2024
About Tsumura & Co. 
Tsumura & Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






